Business Context and Reporting Period
This Form 8-K filing by Eli Lilly & Co. (LLY) reports a significant capital market event dated August 12, 2024, with the transaction closing on August 14, 2024. The filing details the issuance of new senior notes to raise capital.
Key Financial Metrics
The Company issued five series of senior notes with a total aggregate principal amount of $5.0 billion. The net proceeds realized from the offering were approximately $4.96 billion after underwriting discounts but before estimated offering expenses.
| Note Series | Principal Amount | Coupon Rate | Maturity Date |
|---|---|---|---|
| 2027 Notes | $750 million | 4.150% | August 14, 2027 |
| 2029 Notes | $1.0 billion | 4.200% | August 14, 2029 |
| 2034 Notes | $1.25 billion | 4.600% | August 14, 2034 |
| 2054 Notes | $1.25 billion | 5.050% | August 14, 2054 |
| 2064 Notes | $750 million | 5.200% | August 14, 2064 |
Interest on all notes is payable semi-annually. The filing does not provide specific data on current revenue, profit, operating cash flow, or existing debt levels outside of the new issuance.
Material Changes
The primary material change is the increase in the Company's long-term debt obligations by $5.0 billion in principal. This transaction diversifies the Company's debt maturity profile, extending liabilities out to 2064.
Outlook, Risks, and Contingencies
The notes are redeemable at the Company's election at specified redemption prices and terms. An Event of Default as defined in the Indenture could result in the immediate acceleration of the principal amount for any affected series. The offering was registered under Form S-3 (File No. 333-262943). The filing does not contain specific management commentary on future operational guidance or risks beyond the standard debt covenants and default provisions.
Investor Verification Checklist
- Verify the final net proceeds after deducting all estimated offering expenses, as the $4.96 billion figure excludes these costs.
- Review the specific redemption schedules and call protection periods detailed in the Indenture (Exhibit 4.1) and Officers' Certificate (Exhibit 4.3).
- Confirm the impact of the new debt on the Company's overall leverage ratios and credit ratings.
- Check for any subsequent filings regarding the use of proceeds from this $5.0 billion issuance.